Research and Development at Lundbeck

By: Lundbeck  11-11-2011
Keywords: Disease, Research And Development, Nervous System

We devote our entire R&D efforts to develop innovative drugs for treatment of central nervous system (CNS) disorders. Our R&D projects focus on:

  • Depression and anxiety
  • Psychosis
  • Alzheimer’s disease
  • Parkinson’s disease
  • Epilepsy
  • Stroke
  • Alcohol dependence
  • Lennox-Gastaut syndrome

Lundbeck is the only fully-integrated pharmaceutical company in the world, solely devoted to the treatment of central nervous system disorders.

Our efforts to improve the quality of life for those suffering from mental and neurological illnesses have recently resulted in the successful development of

  • Cipralex® - escitalopram – the first ASRI (allosteric serotonin reuptake inhibitor) compound.
  • Ebixa® - is the first and only drug in a new class of compounds for the treatment of Alzheimer’s disease: the NMDA receptor antagonists. Ebixa is a new opportunity to treat moderate to severe Alzheimer’s disease resulting in improvement of daily functioning and cognition.
  • Azilect® - rasagiline – is a novel, potent, second-generation, selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy and as an adjunct therapy in combination with other PD treatments.

Research is our foundation
We acknowledge that the continued growth of our company depends on the achievements of our R&D employees. Thus innovative research and development is  the basis for our future.
Our tasks in Lundbeck R&D are to discover and develop novel therapies and to function as a centre of expertise for the biology of CNS diseases and their therapies.

Research is a way of life
Lundbeck R&D is known worldwide for its pioneering work within the field of psychiatry. We are building on this strength in neurology. As a medium-sized pharmaceutical company, we share common values in the way we work worldwide and keep a clear focus in our R&D strategy.

Our organisation is international. The research organisation is located both in Copenhagen, Denmark and in New Jersey, US.

Development headquarter is situated in Copenhagen, Denmark with clinical research and regulatory personnel spread worldwide.

Research at Lundbeck is based on the efforts of our multi-disciplinary, empowered project teams, our in-house expertise in the CNS disease area, and our state-of-the-art technologies. We work in new, well-equipped laboratories. In each project team, we integrate our advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.

Our strong competencies make Lundbeck an attractive partner, and we have extensive international collaborations with leading academic and institutional research centres and industry partners.

Respect for the individual
At Lundbeck R&D, we work together as individuals towards common goals. We seek to constantly develop and improve our scientific and personal skills and qualifications. This allows us to promote career opportunities for the individual, as well as maintain and develop our competencies as an organization. Publication of our scientific results is a natural part of our participation as active members in the international scientific community.
After all, our growth relies on our talented employees and their innovative efforts.

Keywords: Central Nervous System, Disease, Nervous System, Pharmaceutical Company, Research And Development, Research Centres

Other products and services from Lundbeck


Depression - default

In fact, depression is quite common, affecting 5 – 12 % of the population, and the World Health Organization lists depression as one of the most debilitating conditions. The World Health Organisation now lists depression as the most debilitating conditions in the world, along with high blood pressure and cancer.


Cipralex®/ Lexapro®/ Seroplex® /Seroplexa

How does it work Cells in the brain communicate with each other via electric signals and by using messenger substances, called “neurotransmitters”. Please refer to your local prescribing information to find out about the current approval situation for escitalopram in your country. So-called “serotonin transporters” act like small vacuum cleaners to collect these messengers so they can be used again later.